Methotrexate

Catalog No.S1210 Batch:S121003

Print

Technical Data

Formula

C20H22N8O5

Molecular Weight 454.44 CAS No. 59-05-2
Solubility (25°C)* In vitro DMSO 90 mg/mL (198.04 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Methotrexate, analog of folic acid, is a nonspecific inhibitor of the dihydrofolate reductase(DHFR) of bacteria and cancerous cells as well as normal cells. It forms an inactive ternary complex with DHFR and NADPH. Methotrexate (MTX) induces apoptosis.
Targets
hDHFR [4]
(Activated peripheral T cells)
24 nM
In vitro

Methotrexate (0.1-10 mM) induces apoptosis of in vitro activated T cells from human peripheral blood. Methotrexate achieves clonal deletion of activated T cells in mixed lymphocyte reactions. Methotrexate can selectively delete activated peripheral blood T cells by a CD95-independent pathway. [1]

Methotrexate is taken up by cells via the reduced folate carrier and then is converted within the cells to polyglutamates. Methotrexate leads to diminished production of leukotriene B4 by neutrophils stimulated ex vivo. Methotrexate polyglutamates inhibit the enzyme aminoimidazolecarboxamidoadenosineribonucleotide (AICAR) transformylase more potently than the other enzymes involved in purine biosynthesis. Methotrexate is also known to suppress TNF activity by suppressing TNF-induced nuclear factor-κB activation in vitro, in part related to a reduction in the degradation and inactivation of an inhibitor of this factor, IκBα, and probably related to the release of adenosine. Methotrexate suppresses the production of both TNF and IFN-γ by T-cell-receptor-primed T lymphocytes from both healthy human donors and RA patients. Methotrexate treatment is associated with a significant decrease of TNF-α-positive CD4+ T cells, while the number of T cells expressing the anti-inflammatory cytokine IL-10 increased. [2]

In vivo

Methotrexate increases splenocyte AICAR content, raised adenosine concentrations in exudates from carrageenan-inflamed air pouches, and markedly inhibits leukocyte accumulation in inflamed air pouches in mice. Methotrexate-mediated reduction in leukocyte accumulation is partially reversed by injection of adenosine deaminase (ADA) into the air pouch, completely reverses by a specific adenosine A2 receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX), but not affected by an adenosine A1 receptor antagonist, 8-cyclopentyl-dipropylxanthine in mice. [3]

Protocol (from reference)

Cell Assay:

[5]

  • Cell lines

    Saos-2 cells

  • Concentrations

    0.1 μM

  • Incubation Time

    72 h

  • Method

    Cells were treated with indicated concentrations of drug.

Animal Study:

[3]

  • Animal Models

    Female Balb/c mice

  • Dosages

    0.05-0.5 mg/kg

  • Administration

    i.p.

Customer Product Validation

, , ChemMedChem, 2015, 10(5):804-14.

Data from [Data independently produced by , , Oncotarget, 2016, 7(17):23439-53]

Data from [Data independently produced by , , J Cell Physiol, 2018, 233(5):3713-3722]

Selleck's Methotrexate has been cited by 84 publications

Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index [ Clin Transl Med, 2024, 14(2):e1586] PubMed: 38372422
EFNB1 levels determine distinct drug response patterns guiding precision therapy for B-cell neoplasms [ iScience, 2024, 27(1):108667] PubMed: 38155773
Wogonin inhibits the migration and invasion of fibroblast-like synoviocytes by targeting PI3K/AKT/NF-κB pathway in rheumatoid arthritis [ Arch Biochem Biophys, 2024, 755:109965] PubMed: 38552763
NINJ1 regulates ferroptosis via xCT antiporter interaction and CoA modulation [ bioRxiv, 2024, 2024.02.22.581432] PubMed: 38464226
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments [ EMBO Mol Med, 2023, 15(12):e18199] PubMed: 38037472
USP11-mediated LSH deubiquitination inhibits ferroptosis in colorectal cancer through epigenetic activation of CYP24A1 [ Cell Death Dis, 2023, 14(7):402] PubMed: 37414755
A novel antifolate suppresses growth of FPGS-deficient cells and overcomes methotrexate resistance [ Life Sci Alliance, 2023, 6(11)e202302058] PubMed: 37591722
A novel antifolate suppresses growth of FPGS-deficient cells and overcomes methotrexate resistance [ Life Sci Alliance, 2023, 6(11)e202302058] PubMed: 37591722
miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL [ J Clin Med, 2023, 12(3)1177] PubMed: 36769824
Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids [ Cell Regen, 2023, 12(1):6] PubMed: 36864321

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.